Novartis International AG http://www.novartis.com Novartis pivotal study of Exjade® shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia 2011-12-13T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1571098.shtml New Phase III data shows Novartis JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis 2011-12-13T01:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1570771.shtml Two Novartis Phase III studies show twice as many Ph+ CML patients achieve deeper levels of response with Tasigna® compared to Glivec® 2011-12-12T23:45:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1570773.shtml New data confirms Novartis drug Afinitor® significantly extends time women with advanced breast cancer live without tumor growth 2011-12-08T00:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1569858.shtml Novartis highlights advances for patients with breast cancer and hematological diseases with over 160 SABCS and ASH abstracts 2011-12-02T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1568356.shtml Novartis achieves strong third quarter financial performance and pipeline progress 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1557500.shtml Novartis drug Afinitor® helps women with advanced breast cancer live significantly longer without their disease progressing 2011-09-26T00:01:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1549523.shtml Novartis drug Afinitor® effective in patients with non-cancerous kidney tumors associated with TSC in Phase III trial 2011-09-23T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1549360.shtml Novartis receives EU approval for Votubia®, the first medication to treat children and adults with SEGA associated with TSC 2011-09-08T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1544915.shtml Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors 2011-09-05T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1543887.shtml Novartis drug Afinitor® recommended by CHMP for EU approval to treat patients with advanced pancreatic neuroendocrine tumors 2011-07-22T15:14:25 CET http://www.novartis.com/newsroom/media-releases/en/2011/1532846.shtml Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531819.shtml Phase III trial of Novartis drug Afinitor® met primary endpoint of reducing SEGA tumor size in patients with tuberous sclerosis 2011-07-08T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1529448.shtml Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need 2011-07-05T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1528340.shtml Novartis drug Votubia® recommended by CHMP for approval in the EU for children and adults with SEGA associated with tuberous sclerosis 2011-06-24T14:10:34 CET http://www.novartis.com/newsroom/media-releases/en/2011/1525934.shtml Novartis drug Glivec® shows significant overall survival benefit for patients with GIST after three years of adjuvant treatment vs. one year 2011-06-05T15:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1521228.shtml Novartis JAK inhibitor INC424 shows significant clinical benefit for myelofibrosis patients in two Phase III studies at ASCO 2011-06-04T20:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1521227.shtml Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2011-06-01T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1520486.shtml Novartis drug Votubia® approved as first medication in Switzerland for SEGA, a benign brain tumor associated with tuberous sclerosis 2011-05-11T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1514412.shtml Novartis gains FDA approval for Afinitor® as first new treatment in nearly three decades for patients with advanced pancreatic NET 2011-05-06T00:32:58 CET http://www.novartis.com/newsroom/media-releases/en/2011/1513095.shtml Novartis makes strong start for the year 2011-04-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1507510.shtml Novartis drug Afinitor® recommended by FDA oncology advisory committee for approval to treat advanced NET of pancreatic origin 2011-04-12T20:11:15 CET http://www.novartis.com/newsroom/media-releases/en/2011/1505751.shtml Novartis discontinues clinical trial of Tasigna® for investigational use in newly diagnosed patients with unresectable and/or metastatic GIST 2011-04-11T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1504991.shtml Novartis amends current US FDA application for Afinitor® to seek indication for advanced neuroendocrine tumors of pancreatic origin 2011-04-08T18:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1504913.shtml Second Phase III study of Novartis JAK inhibitor INC424 meets primary endpoint in patients with myelofibrosis 2011-03-15T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1496848.shtml Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET, study published in NEJM shows 2011-02-09T23:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1487280.shtml Innovation drives Novartis to double-digit growth for 2010 2011-01-27T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml European Commission approves Novartis drug Tasigna® for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia 2010-12-23T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1475451.shtml Novartis drug Tasigna® approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia 2010-12-21T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1474393.shtml Novartis investigational JAK inhibitor INC424 data met primary endpoint in Phase III trial of patients with myelofibrosis 2010-12-20T22:05:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1474376.shtml Study of Novartis drug Zometa for potential new use in early breast cancer did not meet primary endpoint in overall study population 2010-12-09T18:57:08 CET http://www.novartis.com/newsroom/media-releases/en/2010/1471079.shtml Study shows Novartis drug Afinitor® plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients 2010-12-09T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1470773.shtml Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2010-12-06T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1469475.shtml Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Glivec® in slowing disease progression in patients with newly diagnosed CML 2010-12-06T13:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1469242.shtml Phase III data published in Lancet show Novartis drug Zometa® improves overall survival in newly diagnosed multiple myeloma patients 2010-12-04T01:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1468811.shtml Data at ASH, SABCS demonstrate commitment of Novartis R&D in advancing treatments for patients with cancer and rare diseases 2010-12-01T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1467354.shtml Tasigna - ENESTnd 24-month update comparing Tasigna to Glivec in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (ASH Abstract #207; Dec. 6; 7:30 AM EST)[3]. Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development 2010-11-11T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1461276.shtml Study in NEJM shows Novartis drug Afinitor® reduces size of SEGAs, benign brain tumors associated with tuberous sclerosis 2010-11-03T22:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1458665.shtml Novartis drug Afinitor® approved by FDA as first medication for children and adults with a benign brain tumor associated with tuberous sclerosis 2010-10-30T04:10:16 CET http://www.novartis.com/newsroom/media-releases/en/2010/1457419.shtml Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumors 2010-10-11T10:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1450718.shtml Novartis drug Tasigna® recommended for approval in European Union to treat patients with newly diagnosed Ph+ chronic myeloid leukemia 2010-09-24T15:07:15 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446754.shtml Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing's disease, a debilitating hormonal disorder 2010-09-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1445885.shtml Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer 2010-09-15T23:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1444522.shtml Novartis drug Tasigna® approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML 2010-08-27T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1440842.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patients 2010-07-01T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1428793.shtml FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec® 2010-06-18T00:15:56 CET http://www.novartis.com/newsroom/media-releases/en/2010/1424982.shtml Study at ASCO shows Novartis drug Afinitor® first to shrink SEGA brain tumors in children and adults with tuberous sclerosis 2010-06-05T23:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421888.shtml Adding Novartis drug Zometa® to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients 2010-06-05T14:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421887.shtml New data at ASCO show Novartis drug Tasigna® surpasses Glivec® in slowing disease progression for newly diagnosed CML patients 2010-06-04T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421566.shtml Pivotal Phase III trial of Novartis drug Afinitor® met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors 2010-06-03T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421290.shtml Data at ASCO show promise of Novartis drugs for patients with life-threatening diseases like CML, multiple myeloma and breast cancer 2010-06-02T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1420819.shtml Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint 2010-05-27T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1419057.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia 2010-02-19T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1386313.shtml Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio 2010-01-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1377026.shtml Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer 2010-01-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1375090.shtml Votubia® de Novartis est le premier traitement autorisé en Suisse pour l'astrocytome sous-épendymaire ŕ cellules géantes (SEGA), une tumeur bénigne du cerveau associée ŕ une sclérose tubéreuse 2011-05-11T07:15:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1514413.shtml Novartis réalise, au deuxičme trimestre, une excellente performance financičre, soutenue par l'essor grandissant de l'innovation 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1431808.shtml Novartis Medikament Afinitor® verzögert signifikant die Krankheitsprogression bei Frauen mit Brustkrebs im fortgeschrittenen Stadium 2011-09-26T00:01:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1549525.shtml Novartis erzielt im zweiten Quartal 2011 starke Finanzergebnisse und erreicht vier wichtige Zulassungen 2011-07-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1531821.shtml Votubia® von Novartis in der Schweiz als erstes Medikament gegen SEGA, einen mit tuberöser Sklerose assoziierten gutartigen Gehirntumor, zugelassen 2011-05-11T07:15:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1514414.shtml Novartis erzielt im dritten Quartal eine hervorragende Performance: Die jüngsten Produkte steuern 20%* zum Umsatz bei; Gilenya wird zugelassen; Alcon wird konsolidiert 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1453748.shtml Gestützt auf eine verstärkte Innovationsdynamik erzielt Novartis im zweiten Quartal eine starke finanzielle Performance 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml Novartis erzielt 2009 Rekordergebnisse - Neu eingeführte Produkte erweisen sich als Wachstumstreiber 2010-01-26T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1377020.shtml